Levodopa facilitates improvements in gait kinetics at the hip, not the ankle, in individuals with Parkinson's disease.

Parkinson's disease symptoms impair gait, limit mobility, and reduce independence. Levodopa improves muscle activation, strength, and coordination; thus, facilitating increased step length, but few studies have evaluated the underlying forces associated with medication-induced gait improvements. Here, we assess the effects of levodopa on gait kinetics in persons with Parkinson's disease. Over two sessions, 13 participants with Parkinson's disease walked on a treadmill while both optimally medicated and after a 12-hour medication withdrawal. Walking was analyzed for spatiotemporal parameters, ranges of motion, anterior-posterior ground reaction forces, joint torques, and powers using an instrumented treadmill and motion capture system. When on medication, participants increased gait speed by significantly improving step length (p = .009) and time (p = .004). Peak propulsive force (p = .001) and hip flexion torques (p = .003) increased with medication while hip extensor and ankle plantarflexor torques did not. While differences in joint power were not significantly different, the optimal medication condition showed medium to large effects, with the largest effect at the hip (dz = 0.84). Our findings suggest the underlying forces responsible for the increases in gait speed are primarily due to increases at the hip, with limited change at the ankle. Disproportionate use of muscle force may be a limiting factor for levodopa's use as an intervention for walking. Future interventions should consider targeting force production deficits during gait in those with Parkinson's disease.